Press releases

22 April 2021

Horama Adds Significant Biopharma Industry and Cell and Gene Therapy Experience to Executive Team

Rodolphe Clerval appointed Chief Executive Officer Nicolas Ferry M.D., Ph.D. appointed Chief Development Officer, and Cedric Cousteix appointed Finance Director Paris, France – April 22nd, 2021 […]
6 November 2020

HORAMA appoints life sciences veteran Benedikt Timmerman as new Chairman

Paris, France, May 18, 2020 – HORAMA, a clinical stage gene therapy company in ophthalmology, today announced that seasoned life sciences executive Dr. Benedikt Timmerman is […]
11 March 2020

HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies

Further expansion of HORAMA gene therapy portfolio to treat Inherited Retinal Dystrophies to lead to second clinical program by 2023 Paris (France) and Leiden (Netherlands), March […]
11 March 2020

HORAMA Strengthens Its Management Team With the Appointment of Rodolphe Clerval as Chief Business Officer (CBO)

Paris, March 11, 2020 – HORAMA, a clinical stage gene therapy company in ophthalmology, today announced that Rodolphe Clerval has been appointed as Chief Business Officer […]
18 September 2018

HORAMA completes its 22.5 million euros “Series B” financing round

Paris (France), September 18th, 2018 – Horama (www.horama.fr), a French biotech company based in Paris and Nantes, which specialises in gene therapy for the treatment of […]
11 July 2018

HORAMA announces initiation of a Phase I/II Clinical Study for HORA-PDE6B, in Retinitis Pigmentosa (RP)

Paris, July 11, 2018 – Horama, a French biotech company based in Paris and Nantes, which specialises in gene therapy for the treatment of rare, inherited […]
16 May 2018

HORAMA Appoints Dr Russell Greig as New Chairman of the Board

Paris, May 15, 2018 – Horama, a French biotech company based in Paris and Nantes, which specialises in gene therapy for the treatment of rare, inherited […]
24 November 2017

Horama raises €19 million in a Series B financing round

Horama raises 19 million euros from new investors (Kurma Partners, Fund+, Pontifax and Idinvest) and existing investors (Omnes Capital, GO Capital and Sham Innovation Santé/Turenne) to […]
11 October 2017

Horama Granted Authorization to Conduct Phase I/II Clinical Study for HORA-PDE6B, in Retinitis Pigmentosa (RP)

Paris , October 11, 2017 – Horama, a French biotech co mpany based in Paris and Nantes, which specialises in gene therapy for the treatment of […]
10 July 2017

Horama Granted Orphan Drug Designation (ODD) In U.S. For Drug Candidate HORA-RLBP1

Paris, France, July 10, 2017 – Horama (www.horama.fr), a French biotech company based in Paris and specialized in gene therapy for the treatment of rare inherited […]